- Open
- 11644.00
- High
- 11748.00
- Low
- 11596.49
- Close
- 11602.00
- Change
- -138.00 (-1.18%)
- Volume
- 359,644
| 3 Aug 2026 | 15:05:00 | Admission of Further Securities to Trading |
| 3 Aug 2026 | 15:00:00 | Total Voting Rights |
| 31 Jul 2026 | 07:30:00 | Datroway approved in EU for TNBC |
| 27 Jul 2026 | 07:10:01 | Update on Ultomiris Phase III trial in HSCT-TMA |
| 27 Jul 2026 | 07:05:01 | Sone-Ve improved survival in gastric cancers |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
AstraZeneca plc is a global, science-led pharmaceutical company focused on the research, development, and commercialization of prescription medicines. It operates primarily in the oncology, bio-pharmaceuticals, and rare disease sectors, delivering a diverse portfolio of products aimed at improving patient outcomes. The company generates revenue through product sales, alliance revenue, and collaboration revenue, serving a wide range of customers across various geographies, including the United States, Europe, and emerging markets.
Lord Goldsmith and 5 other people have interests in this issuer
| 3 Aug 2026 | 15:05:00 | Admission of Further Securities to Trading |
| 3 Aug 2026 | 15:00:00 | Total Voting Rights |
| 31 Jul 2026 | 07:30:00 | Datroway approved in EU for TNBC |
| 27 Jul 2026 | 07:10:01 | Update on Ultomiris Phase III trial in HSCT-TMA |
| 27 Jul 2026 | 07:05:01 | Sone-Ve improved survival in gastric cancers |
| 24 Feb 2026 | 2025 Annul Report & 20-F Information | |
| 18 Feb 2025 | 2024 Annual Report & 20-F Information | |
| 20 Feb 2024 | AstraZeneca PLC Annual Report & 20-F Information 2023 |
AstraZeneca plc is a global, science-led pharmaceutical company focused on the research, development, and commercialization of prescription medicines. It operates primarily in the oncology, bio-pharmaceuticals, and rare disease sectors, delivering a diverse portfolio of products aimed at improving patient outcomes. The company generates revenue through product sales, alliance revenue, and collaboration revenue, serving a wide range of customers across various geographies, including the United States, Europe, and emerging markets.
Lord Goldsmith and 5 other people have interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
AZNAstrazeneca PLC | £179.95bn | +0.1% |
| £83.15bn | +0.4% | |
| £4.63bn | +0.0% | |
| £3.35bn | -0.2% | |
| £258m | -0.1% | |
| £68m | +0.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
AZNAstrazeneca PLC | £179.95bn | +0.1% |
| £83.15bn | +0.4% | |
| £4.63bn | +0.0% | |
| £3.35bn | -0.2% | |
| £258m | -0.1% | |
| £68m | +0.3% |